June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Effect of Bevacizumab, Ranibizumab and Aflibercept on retinal pigment epithelium phagocytosis
Author Affiliations & Notes
  • Patricia Fernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdISNA, Navarra Institute for Health Research, Pamplona, Spain
  • Maria Hernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdISNA, Navarra Institute for Health Research, Pamplona, Spain
  • Sergio Recalde
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdISNA, Navarra Institute for Health Research, Pamplona, Spain
  • Manuel Saenz de Viteri
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Idoia Belza
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Maite Moreno
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Jaione Bezunartea
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Alfredo Garcia-Layana
    Ophthalmology, Clinica Universidad de Navarra, Pamplona, Spain
    IdISNA, Navarra Institute for Health Research, Pamplona, Spain
  • Footnotes
    Commercial Relationships   Patricia Fernandez, None; Maria Hernandez, None; Sergio Recalde, None; Manuel Saenz de Viteri, None; Idoia Belza, None; Maite Moreno, None; Jaione Bezunartea, None; Alfredo Garcia-Layana, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support  RETICS RD12/0034 (Ministerio de Economia y Competitividad. Spain). LGG received a predoctoral grant from the Asociación de Amigos de la Universidad de Navarra.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1207. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Patricia Fernandez, Maria Hernandez, Sergio Recalde, Manuel Saenz de Viteri, Idoia Belza, Maite Moreno, Jaione Bezunartea, Alfredo Garcia-Layana; Effect of Bevacizumab, Ranibizumab and Aflibercept on retinal pigment epithelium phagocytosis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1207.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Controversy exists regarding the safety of vascular endothelial growth factor (VEGF) inhibitors in the retinal pigment epithelium (RPE) and it is currently unknown whether the development of geographic atrophy in patients with age-related macular degeneration (AMD) treated with these drugs is a toxic effect, or otherwise responds to the natural course of the disease. The aim of this work was to evaluate if phagocytosis, one of the most important functions of the RPE, is affected by Bevacizumab, Ranibizumab and Aflibercept and their effect on the main molecular regulators of that function.

Methods : Assays were performed in vitro using the human ARPE-19 cell line. Polarized cell monolayers were treated with clinical concentrations of Bevacizumab, Ranibizumab and Aflibercept during 24 hours and phagocytosis of fluorescent microspheres was assessed at 48 hours by confocal microscopy. We also evaluated the effect of anti-VEGFs in MerTK, phospho-MerTK and a5bv integrin by western blot, as mediators of the phagocytosis process. Moreover, the structure of the cytoskeleton labelled with fluorescent phalloydin (F-actin) was also analyzed by confocal microscopy.

Results : Compared to untreated control cells, exposure to VEGF produced a statistically significant decrease in ARPE-19 cells phagocytosis of fluorescent microspheres (p=0.036). On the contrary, exposure to Bevacizumab and Aflibercept (p=0.016) but not for Ranibizumab (p=0.286) increased the phagocytosis. The expression of MerTK, phospho-MerTK or a5bv integrin was not modified by VEGF treatment and also by any of the anti-VEGFs drugs compared to untreated cells. However, exposure to VEGF produced a disruption of the normal distribution of actin F-actin cytoskeleton fibers that was not observed in cells treated with anti-VEGFs or untreated controls.

Conclusions : Our results suggest that inhibition of VEGF with antiangiogenics treatments increases phagocytosis in RPE cells, while exposure to VEGF has the opposite effect. These results were not explained by differences in the expression of the main molecular regulators of phagocytosis; however, our experiments suggest that they could be related to changes in the normal architecture of the cytoskeleton that was found to be disrupted by exposure to VEGF.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×